The agreement grants Aurigene access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio. Through this license, Aurigene can integrate precision genome editing capabilities into its discovery ...
The CEO of Caszyme, a biotech company in Vilnius, Lithuania, presented details of Cas12l, a novel compact Cas nuclease with a ...
CRISPR-edited tumor-infiltrating lymphocytes are emerging as a promising alternative to CAR T-cell therapy for solid cancers.
CRISPR Cas9 genome editing has transformed the way scientists approach gene therapy, acting like precise DNA scissors that can target and repair hereditary diseases at the genetic level. This ...
Chinese Hamster Ovary (CHO) cells have been the industrial workhorse for production of biopharmaceuticals since the 1980s, with the first CHO-derived product approved by the FDA in 1987. Nearly five ...
Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global ...
Structural alterations of the genome are commonly observed in human cancer and can contribute to tumorigenesis through a variety of mechanisms including the formation of fusion oncoprotein and changes ...
While a US company had earlier developed a similar AI-designed system for human cells, this is the first successful ...
Researchers at the Ruhr University Bochum have developed a novel antiviral concept: Using the CRISPR/Cas13 system, they were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results